Table 4.

Metabolic profile in women and men (n = 393) by predicted stepwise discriminative cardiometabolic risk groups^a

Metabolic variables	sex	Phenotyping study		SE	P-value	FDRd
		Low CMDrf	High CMDrf		Risk
BMI (kg/m2)	women	23.6	29.1	0.44	< 0.01	< 0.01
	men	23.0	28.4	0.58
LDLc (mg/dL)	women	99.5	110	3.51	< 0.01	< 0.01
	men	93.9	114	3.62
HDLc (mg/dL)	women	70.7	56.9	1.44	< 0.01	< 0.01
	men	56.8	47.2	1.98
Cholesterol (mg/dL)	women	177	183	3.53	< 0.01	0.02
	men	161	179	3.72
Triglycerides (mg/dL)	women	70.0	102	6.18	< 0.01	< 0.01
	men	81.2	108	6.83
NEFA (mmol/L)	women	0.32	0.36	0.01	0.06	0.08
	men	0.32	0.33	0.01
Insulin (pmol/L)	women	110	155	9.58	0.03	0.05
	men	104	133	9.36
Glucose (mg/dL)	women	91.3	95.4	1.17	0.24	0.28
	men	94.9	96.9	1.36
HOMA	women	1.32	2.41	0.24	< 0.01	0.01
	men	1.50	2.54	0.22
MCT Matsuda Indexb	women	14.6	9.44	1.22	< 0.01	< 0.01
	men	17.0	12.6	1.96
HbA1C %	women	5.26	5.31	0.05	0.28	0.69
	men	5.27	5.31	0.04
Systolic (mm Hg)	women	117	118	1.11	0.05	0.10
	men	118	122	1.25
Diastolic (mm Hg)	women	65	68	1.01	0.04	0.05
	men	66	72	1.32
Framingham risk (Log)c	women	0.79	1.05	0.09	0.03	0.05
	men	1.94	1.70	0.15

^aMean differences between predicted cardiometabolic risk group BMI, lipid and glucose profiles were examined using Student’s t-test. The model interactions age, sex with predicted risk was not significant

^bMeal challenge test Matsuda Index cut-off of < 8.8 is indicative of insulin resistance

^cThe Risk Calculator estimate 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD), provided by the American Heart Association and the American College of Cardiology. Non-normally distributed risk (%) was log-transformed

^dFalse discovery rate post-hoc p-adjustment